Is Egrifta (Tesamorelin) Safe During Pregnancy?

The Short Answer: Tesamorelin Is Contraindicated in Pregnancy

Stop here if you are pregnant and currently taking tesamorelin. The FDA-approved prescribing information for Egrifta SV states plainly that the drug is contraindicated in pregnancy because animal data demonstrated embryo-fetal toxicity and because no adequate, well-controlled studies exist in pregnant women. This is not a precautionary hedge based on a theoretical concern. It reflects real harm observed in animal reproductive studies at exposures that overlap with those produced by the standard human dose.

If you discovered this article because you are already pregnant and were taking tesamorelin, the first step is to call your prescriber today, not at your next scheduled appointment. The prescriber will help you weigh the risk that has already occurred against next steps, and will likely transition you to monitoring-only for your HIV-associated lipodystrophy during the pregnancy.

Why Tesamorelin Exists and Who Takes It

Tesamorelin is a synthetic analog of endogenous growth hormone-releasing hormone (GHRH). It is approved specifically for the reduction of excess abdominal fat in adults living with HIV who have developed lipodystrophy, a condition often caused by older antiretroviral drugs (particularly thymidine analog nucleoside reverse transcriptase inhibitors) and by HIV-related metabolic dysregulation itself.

Women living with HIV represent a substantial and growing portion of the global HIV population. The CDC estimates that women account for approximately 19% of new HIV diagnoses in the United States, and a significant share of those women are of reproductive age. HIV-associated lipodystrophy affects women differently than men: women are more likely to experience fat accumulation (lipohypertrophy) in the dorsal neck, breasts, and abdomen, while men more commonly show peripheral fat loss. This sex-specific pattern matters when thinking about who receives tesamorelin and therefore who faces a contraindication decision.

What the FDA Label Actually Says

The Egrifta SV prescribing information contains the following language in its pregnancy subsection: tesamorelin "may cause fetal harm when administered to a pregnant woman." The label advises that the drug should be discontinued as soon as pregnancy is recognized. Under the post-2015 FDA pregnancy and lactation labeling rule (PLLR), Egrifta does not carry a letter category (A through X), but the language "may cause fetal harm" maps functionally to what was previously classified as Category X, meaning potential fetal risk outweighs any benefit to the patient.

Animal Reproductive Toxicity Data: What We Know

Because no human pregnancy trials exist, the only direct experimental data on tesamorelin fetal toxicity comes from animal studies. These studies are important to understand, even though animal data does not map perfectly to human outcomes.

Rabbit Embryo-Fetal Development Studies

The FDA label reports that tesamorelin was administered to pregnant rabbits during the period of organogenesis. At doses producing exposures in the range of those seen in humans at the 2 mg/day clinical dose, investigators observed increased post-implantation loss and reduced fetal body weight. These findings were dose-dependent.

Rabbits are a standard model for embryo-fetal toxicity because they respond to teratogenic signals similarly to humans in certain organ systems. A dose that causes embryo-fetal harm in rabbits at human-equivalent exposures is a serious signal, not background noise. The FDA requires this disclosure specifically because the exposure multiple was low, meaning the margin between the therapeutic human dose and the dose that harmed fetal rabbits was not reassuringly large.

Rat Studies and GH-Axis Physiology

Tesamorelin works by binding pituitary GHRH receptors, stimulating growth hormone (GH) secretion, which then drives insulin-like growth factor 1 (IGF-1) production. Both GH and IGF-1 are active during normal fetal development and placentation. Disrupting or exogenously amplifying this axis during a period of active organogenesis carries biological plausibility as a mechanism of harm, independent of the direct animal data.

During pregnancy, endogenous GHRH and the GH/IGF-1 axis shift substantially. Placental GH (a distinct isoform) rises progressively and partially suppresses pituitary GH by mid-pregnancy. Administering an exogenous GHRH analog on top of this altered hormonal milieu could interfere with the normal placental GH signal, though this specific mechanism has not been studied in humans.

What Is Extrapolated vs. Directly Studied

To be transparent about the evidence gap: the animal toxicity data is the entire basis for the contraindication. There are no human case series, no pregnancy registries specific to tesamorelin, and no epidemiological data on outcomes in women who continued tesamorelin inadvertently during the first trimester. What is directly studied: embryo-fetal toxicity in rabbits at clinically relevant doses. What is extrapolated to humans: that a similar risk profile likely applies, based on general pharmacological class and the animal findings. That extrapolation is standard regulatory practice under the PLLR, but it is still extrapolation.

Pregnancy and Lactation: The Required Clinical Summary

This section covers everything you need to know about tesamorelin across the reproductive continuum.

If You Are Trying to Conceive

Tesamorelin should be discontinued before attempting conception. The drug's half-life is short (approximately 26 minutes for the intact peptide), so it clears the system quickly after stopping. However, the downstream effects on IGF-1 levels persist for days to weeks because IGF-1 has a longer half-life and reflects cumulative GH stimulation. No formal washout period has been defined in the label specifically for pre-conception discontinuation, but most clinicians advise stopping at least one full menstrual cycle before attempting pregnancy to allow normalization.

If you are living with HIV and planning a pregnancy, this conversation should happen with both your HIV specialist and your OB-GYN or maternal-fetal medicine provider well in advance. ACOG guidance on HIV in pregnancy emphasizes optimizing antiretroviral therapy and achieving viral suppression before conception, which remains the primary clinical priority.

If You Become Pregnant While Taking Tesamorelin

Discontinue tesamorelin immediately. The FDA label is unambiguous on this point. Contact your prescriber the same day. You and your provider will need to:

• Confirm the pregnancy with a serum beta-hCG if not already confirmed.
• Document the gestational age at the time of tesamorelin exposure.
• Discuss the risk based on the timing and duration of exposure.
• Transition care to an OB provider experienced in HIV in pregnancy.
• Report the exposure to the Antiretroviral Pregnancy Registry if you are also on antiretrovirals, which most women with HIV will be.

The visceral fat that tesamorelin was managing will not disappear overnight, but the metabolic consequences of pausing the drug for 40 weeks of pregnancy are generally preferable to continued fetal exposure.

Breastfeeding and Lactation

Tesamorelin is contraindicated during breastfeeding for two distinct reasons.

First, it is unknown whether tesamorelin or its active metabolites transfer into human breast milk. The National Institutes of Health LactMed database entry for tesamorelin notes that no data exist on the presence of tesamorelin in human milk, the effects on the breastfed infant, or the effects on milk production. Given the absence of safety data, use during lactation cannot be considered safe.

Second, and independently critical: women living with HIV in the United States and other high-resource settings are advised not to breastfeed, regardless of viral load or antiretroviral status. The CDC recommends that women with HIV in the US not breastfeed because antiretroviral therapy does not eliminate all risk of HIV transmission through breast milk, and safe infant formula alternatives are available. This recommendation supersedes any question about tesamorelin's individual lactation safety profile.

Contraception Requirements

If you are of reproductive potential and taking tesamorelin, you need effective contraception. The prescribing information does not specify a particular method, but the principle is clear: unintended pregnancy while on this drug carries a known fetal risk signal. Effective options include:

• Combined hormonal contraceptives (pill, patch, ring): note that some antiretroviral drugs used in HIV treatment, particularly certain protease inhibitors and non-nucleoside reverse transcriptase inhibitors, can reduce hormonal contraceptive efficacy. ACOG recommends reviewing drug-drug interactions between antiretrovirals and hormonal contraception before choosing a method.
• Long-acting reversible contraception (hormonal IUD, copper IUD, implant): generally not affected by antiretroviral interactions and highly effective.
• Barrier methods: effective when used consistently, and also reduce HIV transmission risk.

Sex-Specific Physiology: How Tesamorelin Acts Differently in Women

The GH/IGF-1 axis behaves differently across the female lifespan, and this is not just a pharmacological footnote.

The Menstrual Cycle and GH Secretion

Endogenous GH secretion is pulsatile and sex-steroid dependent. Estrogen amplifies GH pulse amplitude. Women in the follicular phase (higher estrogen) show greater GH secretion than in the luteal phase, and postmenopausal women show significantly blunted GH pulsatility compared to premenopausal women. Studies published in journals including the Journal of Clinical Endocrinology and Metabolism have documented that women have higher baseline GH secretion than men across most of reproductive life.

What this means practically: a woman taking tesamorelin at the standard 2 mg/day dose may experience a larger IGF-1 response at certain cycle phases than at others. This sex-specific pharmacodynamic variability was not systematically studied in the tesamorelin clinical trials, which were conducted primarily in men (reflecting the demographics of the HIV population at the time of the drug's approval). The key Phase 3 trials (LIPO-010A and LIPO-010B) enrolled predominantly male participants, meaning the efficacy and safety data are substantially extrapolated to women.

Perimenopause and Post-Menopause

Perimenopausal and postmenopausal women with HIV-associated lipodystrophy face a double hit: the menopausal transition itself drives visceral fat accumulation independent of HIV, and declining estrogen reduces endogenous GH pulsatility, potentially altering the response to tesamorelin. This population was not studied in the registration trials. If you are perimenopausal or postmenopausal and your provider is considering tesamorelin, ask specifically what data supports its use in women at your life stage. The honest answer is: the data are thin and largely extrapolated from trials in younger men.

PCOS and Metabolic Overlap

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in reproductive-age women, and it frequently co-occurs with insulin resistance and visceral adiposity, the same metabolic phenotype that tesamorelin targets in HIV lipodystrophy. Some women living with HIV also have PCOS. The GH/IGF-1 axis is already dysregulated in PCOS, with IGF-1 often elevated and contributing to androgen excess. Tesamorelin has not been studied in women with PCOS, and exogenous GHRH stimulation in a setting of already-elevated IGF-1 bioactivity is a theoretical concern that has not been formally evaluated.

Who This Is Right For and Who It Is Not

Women Who May Appropriately Use Tesamorelin

Tesamorelin is appropriate for adult women living with HIV who have documented, clinically significant excess visceral fat from lipodystrophy, who are not pregnant, not planning pregnancy in the near term, not breastfeeding, and who have discussed and are using effective contraception. The drug has demonstrated a meaningful reduction in visceral adipose tissue area: in the Phase 3 trials, tesamorelin reduced visceral adipose tissue by approximately 15-18% versus placebo over 26 weeks. For women experiencing significant body image distress or metabolic consequences from lipodystrophy, this is a real clinical benefit.

A practical decision framework for women of reproductive age considering tesamorelin:

1. Confirm you are not pregnant (serum beta-hCG before starting).
2. Establish and document your contraception method before the first dose.
3. Discuss the plan for tesamorelin if you decide to pursue pregnancy in the future.
4. Schedule a contraception review with your provider if your antiretroviral regimen changes, since drug interactions with hormonal contraceptives are common.
5. If your cycle is irregular or delayed at any point on tesamorelin, test for pregnancy before your next scheduled dose.

Women Who Should Not Use Tesamorelin

Tesamorelin is not appropriate if you:

• Are pregnant or suspect you may be.
• Are breastfeeding.
• Have active malignancy (tesamorelin stimulates IGF-1, which can be growth-promoting in cancer).
• Have hypopituitarism or disrupted hypothalamic-pituitary function from another cause.
• Have active or recurring intracranial tumor.

Managing HIV-Associated Lipodystrophy During Pregnancy

If you need to stop tesamorelin because of pregnancy, the lipodystrophy itself does not vanish. Visceral fat accumulates during pregnancy in all women, so baseline lipodystrophy may become more pronounced visually during gestation.

Options During Pregnancy

No pharmacological treatment for HIV-associated lipodystrophy is established as safe in pregnancy. The priority during pregnancy is:

• Maintaining viral suppression with a pregnancy-compatible antiretroviral regimen. ACOG and the Department of Health and Human Services both recommend that antiretroviral therapy continue throughout pregnancy to protect both maternal health and the fetus from vertical transmission.
• Nutritional counseling with an RD experienced in HIV and pregnancy to moderate gestational weight gain in a way that does not compromise fetal growth.
• Postpartum review: after delivery and once the decision about breastfeeding is made (and in the US, the recommendation is not to breastfeed), a conversation about restarting tesamorelin can happen quickly, given its short half-life means a restart can achieve full effect within weeks.

After Delivery: Restarting Tesamorelin

There is no evidence-based mandatory delay before restarting tesamorelin after delivery in a woman who is not breastfeeding. Because the drug does not accumulate over time and works via acute GHRH receptor stimulation, its efficacy profile is the same whether it is a first prescription or a restart. Confirm you are not breastfeeding, confirm contraception is in place, and the prescription can resume.

The Evidence Gap: What We Still Do Not Know

Women have been consistently underrepresented in HIV metabolic research, and tesamorelin's development history reflects that reality. The registration trials enrolled a majority male population. The FDA approved the drug based on that data, with the application of the animal reproductive toxicity findings serving as the basis for the pregnancy contraindication.

What remains genuinely unknown:

• Whether first-trimester tesamorelin exposure in a human produces the same embryo-fetal toxicity pattern seen in rabbits.
• The specific teratogenic mechanism, if any applies to humans.
• Whether the drug's effects on the GH/IGF-1 axis during pregnancy differ from those in non-pregnant adults in a clinically meaningful way.
• The pharmacokinetics of tesamorelin in pregnant women, in whom plasma volume, renal clearance, and protein binding are all substantially altered.
• Long-term outcomes in children born to women who were inadvertently exposed to tesamorelin in early pregnancy.

If you were exposed to tesamorelin during pregnancy, your provider can report the exposure to MedWatch, the FDA's safety reporting program, which helps build the post-marketing dataset for exactly these situations.

Summary of Key Safety Numbers and Guideline Statements

• Standard tesamorelin dose: 2 mg subcutaneously once daily
• Visceral fat reduction vs placebo in Phase 3 trials: approximately 15-18% at 26 weeks
• Tesamorelin half-life: approximately 26 minutes (intact peptide)
• Human pregnancy data: none (animal data only)
• LactMed lactation data: no human data available
• FDA labeling: "may cause fetal harm when administered to a pregnant woman"
• Women as share of new US HIV diagnoses: approximately 19%

The Egrifta SV prescribing label states directly: "Based on animal data, EGRIFTA SV may cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with EGRIFTA SV."

If your clinician has not already had this conversation with you and you are a woman of reproductive age taking tesamorelin, bring it up at your next visit. Ask specifically which contraceptive method is compatible with your antiretroviral regimen. That one conversation could prevent an inadvertent fetal exposure.